On May 19, 2014, Sanofi SA (ADR) (NYSE:SNY), the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), presented Phase II trial (H-030-012) results for an investigational vaccine for the prevention of Clostridium difficile (C. diff) infection (CDI) at the 114th General Meeting of the American Society for Microbiology (ASM). The Phase II trial met its primary objectives, reactions were generally mild and of short duration, and the candidate vaccine generated an immune response against C. diff toxins A and B. These toxins are largely responsible for CDI, which can cause potentially life-threatening gut inflammation and diarrhea. Sanofi SA (ADR) (NYSE:SNY), net profit margin is 9.20% and weekly performance is -0.58%. On last trading day company shares ended up $52.79. Analysts mean target price for the company is $57.88. Sanofi SA (ADR) (NYSE:SNY), distance from 50-day simple moving average (SMA50) is 3.79%.
Pacira Pharmaceuticals Inc (NASDAQ:PCRX), Director Andreas Wicki sold 3,600 shares of Pacira Pharmaceuticals stock on the open market in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $77.80, for a total transaction of $280,080.00. Pacira Pharmaceuticals Inc (NASDAQ:PCRX), advanced 1.97% in last trading session and ended the day on $76.22. PCRX, Gross Margin is 44.40% and its return on assets is 44.10%. Pacira Pharmaceuticals Inc (NASDAQ:PCRX), quarterly performance is 3.94%.
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH)‘s stock had its “overweight” rating reiterated by analysts at Morgan Stanley in a research report issued to clients and investors on Friday. They currently have a $103.00 price objective on the stock. Morgan Stanley’s price objective points to a potential upside of 47.27% from the company’s current price. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), shares moved up 2.34% in last trading session and was closed at $67.71, while trading in range of $66.37 – 67.90. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), year to date (YTD) performance is 63.00%.
On May 22, 2014, TherapeuticsMD Inc (NYSEMKT:TXMD), announced that the Company will present at the Jefferies 2014 Global Healthcare Conference taking place at the Grand Hyatt in New York City on June 2-5 2014. TherapeuticsMD Inc (NYSEMKT:TXMD), ended the last trading day at $3.87. Company weekly volatility is calculated as 5.16% and price to cash ratio as 12.40. TherapeuticsMD Inc (NYSEMKT:TXMD), showed a negative weekly performance of 1.04%.
On May 19, 2014, Endo International plc (NASDAQ: ENDP) (TSX: ENL) announced that affiliates of the company have completed the acquisition of worldwide rights to Sumavel® DosePro® (sumatriptan injection), a needle-free delivery system for subcutaneous use, from Zogenix, Inc. (NASDAQ:ZGNX), for $85 million in cash and rights to additional cash payments based on the achievement of certain commercial milestones. In addition, Endo will assume an existing third party royalty obligation on net sales. The transaction will be financed with Endo’s current cash on hand. Zogenix, Inc. (NASDAQ:ZGNX), weekly performance is -3.30%. On last trading day company shares ended up $2.05. Analysts mean target price for the company is $4.73. Zogenix, Inc. (NASDAQ:ZGNX), distance from 50-day simple moving average (SMA50) is -23.75%.